Skip to main content
Wednesday, August 26, 2026
BTC $78,457 ▼ 0.07%
GOKHSHTEIN.
Live WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
More SectionsDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
LIVE
ADA$0.206down−1.69%ETH$2,471up+1.17%LINK$11.31up+0.21%SOL$96.69up+0.08%BTC$78,457down−0.07%XRP$1.38down−3.75%S&P 5007,680up+0.03%Nasdaq26,127down−0.09%Dow53,479down−0.18%RUT3,007down−0.10%TNX4.66%up+0.54%TYX5.19%up+0.23%FVX4.38%up+0.69%IRX3.69%down−0.40%VIX15.32down−0.84%GOLD$4,650.60down−0.94%SILVER$68.20down−0.71%OIL$81.97down−0.47%DXY99.16up+0.24%NVDA$209.57down−1.64%AAPL$314.00up+1.32%TSLA$345.64down−1.32%META$578.53up+1.49%MSFT$496.71up+1.02%AMZN$260.35down−0.27%GOOGL$341.97down−1.44%Fear & Greed65 — GreedADA$0.206down−1.69%ETH$2,471up+1.17%LINK$11.31up+0.21%SOL$96.69up+0.08%BTC$78,457down−0.07%XRP$1.38down−3.75%S&P 5007,680up+0.03%Nasdaq26,127down−0.09%Dow53,479down−0.18%RUT3,007down−0.10%TNX4.66%up+0.54%TYX5.19%up+0.23%FVX4.38%up+0.69%IRX3.69%down−0.40%VIX15.32down−0.84%GOLD$4,650.60down−0.94%SILVER$68.20down−0.71%OIL$81.97down−0.47%DXY99.16up+0.24%NVDA$209.57down−1.64%AAPL$314.00up+1.32%TSLA$345.64down−1.32%META$578.53up+1.49%MSFT$496.71up+1.02%AMZN$260.35down−0.27%GOOGL$341.97down−1.44%Fear & Greed65 — Greed
GOKHSHTEIN.
Media · Est. 2019
The front page of everything. Breaking news and sharp analysis across politics, markets, crypto, technology, and sports — with live market data built in.
Markets
Market OverviewDigital AssetsU.S. EquitiesMacro & RatesResearch
Editorial
Politics & PolicyTechnologySports BusinessResearch
Terminal
GMarketsGo PRO
Company
AboutContactThe NetworkEditorial StandardsCorrectionsAdvertiseSubscribe
Legal
Privacy PolicyTerms of ServiceDisclosures
© 2026 Gokhshtein Media. All rights reserved.
PrivacyTermsDisclosures
Tag

drug approval

1 article

Revolution Medicines' Rasonque Wins FDA Nod in Pancreatic Cancer
U.S. Equities3h ago
Revolution Medicines' Rasonque Wins FDA Nod in Pancreatic Cancer
Daraxonrasib cleared 6.5 months early with Phase 3 data showing median 13.2-month survival versus 6.7 months on chemotherapy in second-line metastatic pancreatic cancer.